Company Description
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.
The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3.
Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,965 |
| CEO | Ingrid Zhang |
Contact Details
Address: 2101 Cottontail Lane Somerset, New Jersey 08873 United States | |
| Phone | 737 317 5050 |
| Website | legendbiotech.com |
Stock Details
| Ticker Symbol | LEGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 1801198 |
| CUSIP Number | 52490G102 |
| ISIN Number | US52490G1022 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carlos Santos Garcia | Chief Financial Officer |
| Ananda Elizabeth Martin Esq., J.D. | Global Compliance Officer |
| Robert Staloff | General Counsel |
| Dr. Ying Huang Ph.D. | Advisor |
| Dr. Yuhong Qiu Ph.D. | Interim Head of Research and Development and Senior Vice President of Regulatory Affairs |
| Birk Vanderweeen | Senior Vice President of Global Manufacturing and Supply |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 144 | Filing |
| Sep 25, 2026 | 6-K | Report of foreign issuer |
| Sep 24, 2026 | 6-K | Report of foreign issuer |
| Sep 22, 2026 | 144 | Filing |
| Sep 22, 2026 | 144 | Filing |
| Sep 15, 2026 | 6-K | Report of foreign issuer |
| Sep 14, 2026 | 6-K | Report of foreign issuer |
| Aug 18, 2026 | 6-K | Report of foreign issuer |
| Aug 11, 2026 | 6-K | Report of foreign issuer |
| Aug 6, 2026 | 6-K | Report of foreign issuer |